.jpg)
1 hour ago
3
Article content
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion Leaders (KOLs) Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco. They will join company leadership to discuss the Company’s six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients with early Alzheimer’s disease (AD). The analysis will focus on blinded aggregate safety data and overall trends in select biomarkers across study participants.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Webinar Details
Date: July 28, 2026
Time: 8:00-9:00 am ET
Speakers (ProMIS): Neil Warma, Chief Executive Officer, and Dr. Larry Altstiel, Chief Medical Officer
KOLs: Dr. Will Mantyh and Dr. Michael Weiner
Registration link: https://lifescievents.com/event/it38tlq/
About Dr. Will Mantyh
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
William G. Mantyh, M.D. is an Associate Professor with Tenure in Behavioral/Cognitive Neurology at the University of Minnesota, specializing in Alzheimer’s disease and related neurodegenerative disorders. His research focuses on blood-based biomarkers, APOE genetics, and expanding equitable access to Alzheimer’s diagnosis and treatment in underserved communities. He is the principal investigator of a $3.7 million NIH grant studying Alzheimer’s blood tests in Native American communities and serves as M Health Fairview’s Practice Leader for new biomarker and anti-amyloid infusion care models. Dr. Mantyh earned his M.D. from the University of Minnesota, completed his internship and neurology residency at Mayo Clinic, and finished a fellowship in Behavioral Neurology at the University of California, San Francisco.
Article content
Article content
About Dr. Michael Weiner
Article content
Dr. Weiner is UCSF Professor Emeritus of Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology, and the CEO of the AI voice company, Vaicro. He has conducted research for over 60 years and is Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the BrainHealthRegistry.org. He was one of the first to perform nuclear magnetic resonance on an intact animal. He then pursued development of MRI/MRS as a clinical tool and established the Center for Imaging of Neurodegenerative Diseases at the San Francisco VAMC. Dr. Weiner has published over 1,030 peer-reviewed articles, trained dozens of postdoctoral fellows, and received numerous honors including the Alzheimer’s Association’s Nancy and Ronald Reagan Award, the Potamkin Prize of the American Academy of Neurology, a Docteur Honoris Causa Degree from Paul Sabatier University, Toulouse, France, and the Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research, from the Alzheimer’s Association in 2021. His current interest is AI applications to ADRD research, especially development of AI-powered conversational voice agents to perform clinical and cognitive assessments.
English (US)